Peptide FAQs
One question. One paragraph. The evidence and its limitations, together.
BPC-157Does BPC-157 speed tendon or ligament healing?
The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[1] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[2] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[2] Pain relief and tissue repair are different outcomes: a report of less pain does not show that a torn tendon has regained its structure or mechanical strength.[1] The rat experiment assessed surgically repaired Achilles tendons, so it also cannot determine whether BPC-157 accelerates recovery from the range of tendon injuries seen in clinical practice.[2]
BPC-157What does the human knee-pain study show?
Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[1] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[1] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[1] The finding is therefore a preliminary signal of reported symptom improvement, rather than evidence that BPC-157 treats a defined knee disorder or repairs damaged cartilage.[1]
BPC-157What evidence supports muscle-injury recovery?
Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[3][4] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[5] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[3][4][5] The experiments address different injuries and treatment conditions, making their results specific to those models rather than a single, established effect on muscle recovery.[3][4][5] They do not answer whether an athlete or a patient undergoing rehabilitation would regain strength sooner, return to activity earlier, or experience fewer complications.[3][4][5]
BPC-157Does BPC-157 heal the gut or treat inflammatory bowel disease?
Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[6][7] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[8] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[6][8] Damage caused experimentally by concentrated alcohol is a different research problem from treating chronic inflammatory bowel disease in people.[7] The animal results provide a reason to investigate gastrointestinal effects, but the incomplete human report does not establish which patients would benefit, how large the benefit would be, or whether it would persist.[6][7][8]
BPC-157Has BPC-157 been studied for bladder pain?
An uncontrolled retrospective report described twelve women treated by cystoscopic bladder injection; ten reported complete symptom resolution and two partial improvement.[9] The paper describes follow-up timing inconsistently, and the lack of a comparator prevents attributing improvement to BPC-157.[9] This procedure-specific report does not establish that oral or subcutaneous products treat bladder pain.[9] The small sample and retrospective symptom assessments make this an exploratory observation, not a controlled estimate of treatment benefit.[9] Its findings apply to the particular patients and bladder procedure described, and cannot supply a general treatment protocol for urinary symptoms.[9]
BPC-157Does the large clinical-note study prove BPC-157 works?
A September 2026 preprint identified 1,039 documented users; 279 of the 354 with a recorded response direction had reported improvement, while 685 lacked a recorded response direction.[10] It was not peer reviewed at this check, and missing outcomes, co-treatments and no control group prevent interpreting these counts as an effectiveness rate.[10] The much larger number of documented users improves the description of real-world use, but it does not resolve the missing outcomes or introduce the comparison group needed to estimate a treatment effect.[10]
BPC-157Has BPC-157 been shown to be safe in humans?
The two-person intravenous pilot reported no adverse effects during three days of monitoring, but both participants had previous exposure.[11] This small, selected sample cannot establish routine or long-term safety.[11] The clinical-note preprint also describes neuropsychiatric, skin or injection-site, and gastrointestinal symptoms, without establishing causation or reliable event rates.[10] Three days of observation in two previously exposed adults provides little information about uncommon reactions, the consequences of repeated treatment, or effects that emerge after prolonged exposure.[11] The larger clinical-note report adds descriptions of symptoms encountered in practice, but its retrospective records cannot reliably distinguish adverse drug reactions from symptoms associated with illness or other treatments.[10]
BPC-157Does BPC-157 increase growth hormone?
A cell-culture study found increased growth-hormone receptor expression in rat tendon fibroblasts.[12] That is different from demonstrating increased circulating growth hormone, and it does not validate combining BPC-157 with growth-hormone secretagogues in people.[12] Receptors describe how a cell may respond to a hormone; this experiment did not measure a rise in blood growth-hormone levels or test a clinical benefit from raising those levels.[12]
BPC-157Does combining BPC-157 with TB-500 work better?
The knee case series included only four recipients of BPC-157 plus thymosin beta-4 and did not randomize treatment.[1] A rat Achilles study found no additional benefit from its BPC-157/TB-500 combination over monotherapy, with small endpoint samples.[2] Neither study establishes the benefit or safety of commercial peptide blends in people.[1][2]
BPC-157Does oral BPC-157 work as well as an injection?
Oral administration produced effects in some rat injury experiments, but those experiments did not measure clinical equivalence in humans.[3][6] A pharmacokinetic study examined intravenous and intramuscular administration in rats and dogs; it did not evaluate human oral absorption.[13] These sources do not establish that capsules and injections are interchangeable.[3][13] A response in an animal injury model and a measurement of drug exposure answer different questions; neither establishes that a marketed capsule delivers the same exposure or effects as an injection in a person.[3][6][13] Consequently, route-specific findings should remain attached to the formulation, species and administration method actually studied.[3][6][13]
BPC-157What is known about BPC-157’s half-life?
The pharmacokinetic paper reported mean intact-peptide half-lives below thirty minutes in tested rat and dog regimens.[13] The two-person human intravenous paper measured clinical laboratory markers rather than BPC-157 concentrations.[11] These studies therefore do not establish a human half-life or dosing frequency.[11][13] A short animal plasma half-life also does not, by itself, tell us how long a biological effect lasts or how frequently a person would need treatment.[13]
TB-500Is TB-500 the same as thymosin beta-4, and does it heal injuries?
The name TB-500 requires clarification before interpreting any study.[14] FDA describes TB-500 as the thymosin beta-4 fragment LKKTETQ and reports that it has not identified human exposure data for that fragment.[14] Full-length thymosin beta-4 has been studied in humans, including investigational eye drops for corneal disease, but that is a different molecule, formulation, target tissue, and route.[15] Those trials cannot validate a vial marketed as TB-500 for tendon repair or whole-body recovery.[14][15] For injury healing with the fragment, direct human clinical benefit remains unestablished in the evidence reviewed here.[14][15]
GHK-CuDoes topical GHK-Cu improve skin quality?
The selected topical trial provides limited, procedure-specific evidence for GHK-Cu.[16] In a randomized study after carbon dioxide laser resurfacing, 13 patients completed follow-up.[16] Participants using the copper-peptide regimen reported greater improvement in overall skin quality, but objective assessments found no significant between-group improvement in wrinkles, overall skin quality, or resolution of redness.[16] This small, procedure-specific study does not establish that every copper-peptide serum reduces wrinkles or reverses skin aging.[16] Subjective satisfaction and objectively measured improvement should remain separate when judging a cosmetic claim, and findings from a topical regimen should not be transferred to injections.[16]
GHK-CuIs injectable GHK-Cu better than a topical serum?
Clinical superiority of injected GHK-Cu over topical GHK-Cu has not been demonstrated in the human evidence reviewed here.[14][16] A topical study cannot establish the effectiveness or safety of systemic injection, because exposure and delivery are different.[16] FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[14] The argument that injection must work better because it bypasses the skin barrier is a mechanistic hypothesis, not a clinical result.[14][16] A useful comparison would require a controlled human study of defined formulations, relevant skin outcomes, and adverse events.[14][16]
CJC-1295Does raising growth hormone with CJC-1295 prove better recovery or muscle growth?
CJC-1295 has demonstrated hormonal activity in humans, but that does not establish improved recovery or muscle performance.[17] Two short randomized, placebo-controlled trials of the long-acting formulation found increases in growth hormone and IGF-1 in healthy adults.[17] These were pharmacology studies, not demonstrations of faster injury healing, greater strength, better sleep, or longer life.[17] A biomarker response is useful for understanding what a compound does, while meaningful benefit requires direct clinical outcomes.[17] Results from the studied long-acting molecule should also not be automatically assigned to products marketed as CJC-1295 without DAC or to combination products.[17]
IpamorelinDoes ipamorelin, alone or with CJC-1295, improve sleep and recovery?
The human studies reviewed here do not establish that ipamorelin improves sleep quality or training recovery, either alone or combined with CJC-1295.[18][19] Early human work examined its pharmacokinetics and growth-hormone response, while a later randomized trial studied intravenous ipamorelin after bowel surgery.[18][19] Neither setting directly tests the sleep or recovery claims made for subcutaneous combinations.[18][19] Evidence that a compound stimulates growth hormone is not interchangeable with evidence of better sleep architecture, physical function, or recovery time.[18][19] A combination also requires its own evaluation rather than assuming that separate hormone effects add up to clinical benefit.[18][19]
SemaglutideHow much weight loss did semaglutide produce in a major clinical trial?
In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[20] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[20] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[20] Gastrointestinal adverse effects were common, and the trial used a defined pharmaceutical formulation under clinical supervision.[20] Its results should not be generalized to every dose, route, or patient group.[20]
SemaglutideWhat happens to weight after stopping semaglutide?
Weight regain was substantial after treatment ended in the STEP 1 extension.[21] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[21] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[21] It nevertheless shows that a successful treatment period does not guarantee permanent weight maintenance after withdrawal.[21]
TirzepatideHow much weight loss did tirzepatide produce in SURMOUNT-1?
SURMOUNT-1 randomized 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes.[22] Across the three studied tirzepatide groups, average weight reduction at 72 weeks ranged from 15.0% to 20.9%, compared with 3.1% with placebo.[22] The size and randomized design support a strong conclusion about average weight reduction under the trial conditions.[22] Gastrointestinal adverse effects were the most common and occurred mainly during dose escalation.[22] These figures describe a specific pharmaceutical product, population, and treatment program; they do not establish equivalent effects for products of unknown composition or guarantee an individual response.[22]
TirzepatideDoes tirzepatide cause more weight loss than semaglutide?
In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without diabetes.[23] Among 751 randomized participants, mean weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide, using the maximum tolerated trial regimens.[23] The trial was open-label and manufacturer funded, which should be considered alongside its direct randomized comparison.[23] Gastrointestinal adverse events were common in both groups.[23] The finding applies to the formulations and regimens compared; it does not prove that one medicine is the best choice for every individual or every clinical outcome.[23]
TirzepatideDo people regain weight when they stop tirzepatide?
Many participants regained weight after tirzepatide withdrawal in SURMOUNT-4.[24] After a 36-week initial treatment period, 670 participants were randomized either to continue tirzepatide or switch to placebo.[24] During the next 52 weeks, the placebo group gained an average 14.0% relative to its weight at randomization, while those continuing tirzepatide lost a further 5.5%.[24] This is direct randomized evidence that continued treatment helped maintain weight reduction in participants who reached randomization.[24] It does not mean everybody regains the same amount, and its selected population excludes people who discontinued during the initial treatment phase.[24]
Collagen peptidesDo oral collagen peptides help activity-related joint pain?
Oral collagen hydrolysate may improve some measures of activity-related joint discomfort, but the evidence is less decisive than marketing often suggests.[25] A 24-week randomized trial recruited 147 athletes and analyzed 97; several pain measures favored collagen over placebo.[25] The missing participants, multiple outcomes, and specific athletic population limit confidence and generalizability.[25] Reduced pain also does not demonstrate cartilage regeneration or accelerated repair of a torn tendon.[25] This result concerns an oral nutritional preparation with a particular composition, so it should not be used to justify injectable peptides or to assume that every collagen product is clinically equivalent.[25]
Collagen peptidesDo oral collagen peptides improve skin elasticity?
A randomized trial reported improved skin elasticity with a specific oral collagen preparation.[26] In one double-blind trial, 69 women aged 35–55 were assigned collagen hydrolysate or placebo for eight weeks; elasticity improved relative to placebo, while moisture-related findings were not statistically significant.[26] This is a short-term signal in a narrow population rather than proof of broad skin rejuvenation.[26] Results depend on the product and endpoint, and statistical improvement does not automatically establish a noticeable cosmetic difference.[26] The trial does not support claims about injectable collagen-related peptides or permanent reversal of skin aging.[26]
SemaglutideDoes a 99% purity claim mean a peptide is safe to inject?
A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[27] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[27] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[27] The sample was small and selected, so it cannot estimate the failure rate of the entire market.[27] It does demonstrate why a seller's percentage or certificate cannot, by itself, establish that a finished injectable product is suitable for human use.[27]
Semaglutide · SafetyWhat safety issues are established for Wegovy?
The Wegovy label lists common reactions including nausea, vomiting, diarrhea and constipation; serious warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.[28] The thyroid-tumor warning comes from rodent findings whose relevance to humans is unknown.[28] The Medication Guide directs stopping treatment and seeking immediate help for persistent severe abdominal pain or serious allergic symptoms, including breathing difficulty or face/throat swelling.[28] Patients should disclose treatment before anesthesia or deep sedation because aspiration has been reported.[28]
Read in the peptide guideSemaglutide · ContraindicationsWhat are the formal contraindications and separate precautions?
The Wegovy label’s formal contraindications include personal/family medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and semaglutide/excipient hypersensitivity.[28] Separate pregnancy guidance for weight management directs discontinuation when pregnancy is recognized and at least two months before planned pregnancy.[28] Breastfeeding is not recommended with tablets; injection labeling calls for individualized assessment because milk-transfer and infant-effect data are missing.[28] Severe gastroparesis is a separate not-recommended precaution.[28]
Read in the peptide guideSemaglutide · InteractionsWhich medication interactions require attention?
Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying may affect oral medicines, including those requiring close monitoring.[28]
Read in the peptide guideSemaglutide · Forms & dosingWhich forms and administration instructions are covered?
Wegovy tablets and subcutaneous injections have separate escalation, maintenance, administration and switching instructions.[28]
Read in the peptide guideSemaglutide · Results & stoppingWhat does the label say about duration and treatment interruptions?
Wegovy is labeled for long-term weight maintenance; its Medication Guide directs clinician discussion after multiple missed weekly injections.[28]
Read in the peptide guideSemaglutide · Product qualityDo compounded products have the same quality evidence?
FDA identifies semaglutide sodium and acetate as different active ingredients from those in approved drugs and says their chemical and pharmacologic equivalence is not established.[29] The agency has also received reports of dosing errors with compounded semaglutide injections, including cases requiring hospitalization.[29]
Read in the peptide guideSemaglutide · StatusWhat does U.S. approval mean for this page?
Wegovy has approved weight-management indications; eligibility and other indications differ between oral and injectable formulations.[28] Compounded semaglutide is not FDA-approved and does not undergo the agency's premarket review for safety, effectiveness and quality.[30]
Read in the peptide guideTirzepatide · SafetyWhat safety issues are established for Zepbound?
The Zepbound label lists common reactions including nausea, vomiting, diarrhea and constipation; serious warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.[31] The thyroid-tumor warning comes from rodent findings whose relevance to humans is unknown.[31] The Medication Guide directs stopping treatment and seeking immediate help for persistent severe abdominal pain or serious allergic symptoms, including breathing difficulty or face/throat swelling.[31] Patients should disclose treatment before anesthesia or deep sedation because aspiration has been reported.[31]
Read in the peptide guideTirzepatide · ContraindicationsWhat are the formal contraindications and separate precautions?
The Zepbound label’s formal contraindications include personal/family medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and serious tirzepatide/excipient hypersensitivity.[31] Separate pregnancy guidance directs discontinuation when pregnancy is recognized.[31] Breastfeeding requires benefit–risk assessment: infant and milk-production effects are unknown despite low milk transfer in a single-dose study.[31] Severe gastroparesis is a separate not-recommended precaution.[31]
Read in the peptide guideTirzepatide · InteractionsWhich medication interactions require attention?
Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying may affect oral-drug absorption.[31] Reduced oral contraceptive effectiveness requires additional precautions after initiation and dose escalation.[31]
Read in the peptide guideTirzepatide · Forms & dosingWhich forms and administration instructions are covered?
Zepbound is injected subcutaneously weekly; pen/vial instructions and dosing depend on presentation, indication and tolerability.[31]
Read in the peptide guideTirzepatide · Results & stoppingWhat does the label say about duration and treatment interruptions?
Zepbound is labeled for long-term weight maintenance; its prescribing information provides instructions for missed weekly doses.[31]
Read in the peptide guideTirzepatide · Product qualityDo compounded products have the same quality evidence?
FDA reports fraudulent compounded tirzepatide labeling and concerns about shipping temperatures, dosing and dose escalation for unapproved GLP-1 products.[29] Compounded drugs can meet particular medical needs, but contamination or incorrect active-ingredient amounts can cause serious harm.[30]
Read in the peptide guideTirzepatide · StatusWhat does U.S. approval mean for this page?
Zepbound is approved for weight management in eligible adults and moderate-to-severe obstructive sleep apnea in adults with obesity.[31] Compounded tirzepatide is not FDA-approved and has not undergone FDA premarket review for safety, effectiveness and quality.[30]
Read in the peptide guideBPC-157 · SafetyWhat safety concerns does FDA identify?
FDA identifies immunogenicity concerns and limited route-specific safety information.[14]
Read in the peptide guideBPC-157 · ContraindicationsHas safety been established for pregnancy or people concerned about cancer?
FDA's 2026 assessment identified no carcinogenicity studies and incomplete reproductive testing for the evaluated BPC-157 substances and routes.[8] Those gaps leave pregnancy and cancer-related safety unresolved; they do not establish either a proven-safe population or a demonstrated human cancer effect.[8] These are missing safety assessments, rather than evidence that every potential risk has been excluded.[8] The available assessment therefore cannot define an evidence-based list of circumstances in which BPC-157 can be assumed safe, particularly where reproductive or cancer-related risks are the concern.[8]
Read in the peptide guideBPC-157 · InteractionsCan BPC-157 be combined safely with medicines or other peptides?
The human reports were not designed to establish drug-interaction safety.[1][11] Rat experiments involving corticosteroids do not establish compatibility in people.[5] Observations involving more than one treatment do not establish that a combination is safe or that the treatments act independently.[1][11] The reviewed human evidence consequently does not support a validated interaction list or a general assurance that adding BPC-157 to an existing regimen is safe.[1][11]
Read in the peptide guideBPC-157 · Forms & dosingWhat human absorption data are available for different routes?
FDA's 2026 review found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal BPC-157.[8] This limits the ability to translate a dose used in one setting into an equivalent dose for another route.[8] A clinical dosing recommendation would require evidence connecting a defined formulation and exposure to a meaningful benefit and an acceptable safety profile, which this assessment does not establish for those routes.[8]
Read in the peptide guideBPC-157 · Results & stoppingHow quickly should results appear, and what happens after stopping?
The knee-pain report used variable retrospective follow-up, so it cannot establish a reliable healing timeline or cycling schedule.[1] The clinical-note preprint recorded discontinuation for several reasons but did not test a tapering or withdrawal protocol.[10] Retrospective reports of improvement cannot determine the expected time to benefit for a new patient or show whether symptom changes correspond to healed tissue.[1] Likewise, records of discontinuation do not establish whether tapering is necessary or whether a particular cycle reduces adverse effects.[10]
Read in the peptide guideBPC-157 · Product qualityDoes a certificate of analysis establish product quality?
FDA’s assessment identified inconsistent substance naming and incomplete impurity characterization.[8] For injectable products, it also identifies sterility, bacterial endotoxins and particulates as relevant quality attributes; a purity percentage alone does not cover those attributes.[8] Identity, impurity characterization and the quality requirements of the intended route are separate questions; a reported percentage of chemical purity addresses only part of that assessment.[8] Even an analytically characterized substance does not establish that the finished formulation is clinically effective or safe for a particular use.[8]
Read in the peptide guideBPC-157 · StatusWhat is the U.S. regulatory status described by FDA?
FDA's 2026 briefing states that neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug.[8] At the October 3, 2026 source check, FDA’s risk page listed BPC-157 under nominations withdrawn by their nominators.[14]
Read in the peptide guideTB-500 · SafetyHas the TB-500 fragment been shown safe in people?
For TB-500, FDA reports no identified human exposure data and flags possible immunogenicity associated with aggregation and peptide impurities.[14]
Read in the peptide guideTB-500 · ContraindicationsWhich populations have established safety or contraindications?
FDA's assessment does not establish a safe population for the TB-500 fragment, including pregnancy, breastfeeding or people with serious medical conditions.[14]
Read in the peptide guideTB-500 · InteractionsAre combinations with medicines or BPC-157 established as safe?
The cited RGN-259 trial tested full-length thymosin beta-4 eye drops, not interactions involving the injected TB-500 fragment.[32] The four-person combination subgroup in the BPC-157 knee report used a product described as thymosin beta-4 and cannot establish the safety of fragment-containing combinations.[1]
Read in the peptide guideTB-500 · Forms & dosingIs TB-500 interchangeable with full-length thymosin beta-4?
FDA identifies TB-500 as the thymosin beta-4 fragment LKKTETQ.[14] RGN-259 research used full-length thymosin beta-4 in an ophthalmic formulation; its study regimen does not establish an injectable fragment dose.[32]
Read in the peptide guideTB-500 · Results & stoppingDo human trials establish a recovery timeline or stopping schedule?
In the 18-person trial of full-length thymosin beta-4 eye drops, the prespecified four-week healing comparison was not statistically significant, although a secondary assessment favored treatment two weeks after cessation.[32] These corneal findings do not establish an injury-recovery timeline, durable benefit or stopping schedule for injected TB-500 fragment.[32]
Read in the peptide guideTB-500 · Product qualityWhat does a tested or compounded label establish?
FDA's fragment assessment flags aggregation and peptide impurities.[14] Separately, FDA explains that compounded medicines are not reviewed before marketing for safety, effectiveness or quality, and contamination or incorrect strength can cause serious harm.[30]
Read in the peptide guideTB-500 · StatusHow does FDA currently list the TB-500 fragment?
FDA currently places thymosin beta-4 fragment LKKTETQ, also called TB-500, among withdrawn bulk-substance nominations.[14] Compounding itself does not confer FDA approval on the resulting medicine.[30]
Read in the peptide guideGHK-Cu · SafetyAre topical and injectable GHK-Cu equally well characterized for safety?
FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[14] The cited skin trial studied topical products after laser resurfacing and cannot establish injection safety.[16]
Read in the peptide guideGHK-Cu · ContraindicationsDoes the evidence establish safety during pregnancy or with copper-handling disorders?
The cited topical trial reports cosmetic outcomes in 13 completers; its abstract does not establish safety during pregnancy, breastfeeding or in copper-handling disorders.[16]
Read in the peptide guideGHK-Cu · InteractionsAre interactions with medicines, supplements or other peptides established?
The cited trial compared topical skin-care regimens, not medication combinations; it does not establish compatibility with copper supplements, chelators or injectable peptide combinations.[16]
Read in the peptide guideGHK-Cu · Forms & dosingCan a topical study supply an injection dose or mixing protocol?
The cited randomized study examined topical GHK-Cu skin care after CO2 laser resurfacing; it provides no tested injection dose or injectable-combination protocol.[16]
Read in the peptide guideGHK-Cu · Results & stoppingHow long do results take, and do they persist after stopping?
At 12 weeks, the 13-completer topical trial found no significant between-group objective improvement in wrinkles or overall skin quality, although patient-reported satisfaction favored GHK-Cu.[16] The abstract does not report a controlled withdrawal comparison establishing persistence after stopping.[16]
Read in the peptide guideGHK-Cu · Product qualityWhat quality concerns apply to injectable products?
FDA specifically identifies aggregation and peptide impurities as concerns for injectable GHK-Cu.[14] FDA also warns that contamination or incorrect strength in compounded medicines can cause serious harm.[30]
Read in the peptide guideGHK-Cu · StatusDoes cosmetic availability mean GHK-Cu is an approved injectable medicine?
FDA lists injectable GHK-Cu among withdrawn bulk-substance nominations.[14] U.S. cosmetic products generally do not undergo FDA preapproval, except certain color additives; therapeutic claims can cause a product marketed as a cosmetic to qualify as a drug.[33]
Read in the peptide guideCJC-1295 · SafetyWhat safety problems have been reported with CJC-1295?
FDA identifies increased heart rate and systemic vasodilatory reactions among serious events associated with CJC-1295, while emphasizing the limited clinical data.[14] Its 2024 assessment also describes injection-site reactions, headache, flushing, dizziness and low blood pressure in early studies; the long-term safety profile remains unknown.[34]
Read in the peptide guideCJC-1295 · ContraindicationsWho should avoid CJC-1295, and are contraindications established?
The cited trials enrolled healthy adults aged 21–61; that study population does not establish a complete contraindication list or suitability for people with medical conditions.[17] FDA found no data informing pediatric safety and identified gaps in reproductive and long-term safety research, so these populations cannot be assumed safe on the basis of the adult trials.[34]
Read in the peptide guideCJC-1295 · InteractionsDoes research establish that CJC-1295 is safe to combine with ipamorelin?
Separate human experiments found that CJC-1295 increased GH and IGF-1 and that ipamorelin stimulated GH, but these cited experiments did not test the combination.[17][18] Our interpretation is that these hormone-response findings cannot establish the safety or added clinical benefit of combining the two.[17][18]
Read in the peptide guideCJC-1295 · Forms & dosingAre CJC-1295 with DAC and without DAC interchangeable?
FDA distinguishes CJC-1295 substances with and without a drug affinity complex (DAC), and notes that published clinical references appear to involve DAC-containing material without specifying its salt form.[34] Consequently, the long-acting trial cannot establish an interchangeable dosing schedule for products labeled without DAC.[17][34]
Read in the peptide guideCJC-1295 · Results & stoppingHow long do CJC-1295 effects last, and what happens after stopping?
In the early trials, the estimated half-life was 5.8–8.1 days, and mean IGF-1 remained above baseline for up to 28 days after repeated administration.[17] These measurements describe drug exposure and hormone responses; they do not establish durable improvements in recovery or body composition after treatment ends.[17]
Read in the peptide guideCJC-1295 · Product qualityWhat does a purity claim establish about a CJC-1295 product?
FDA found that certificates it reviewed for CJC-1295 DAC free base often reported purity without an impurity profile, and concluded that this material was not well characterized.[34] FDA separately warns that contamination or incorrect active-ingredient amounts in compounded drugs can cause serious harm, so a purity percentage alone cannot establish finished-product safety.[30]
Read in the peptide guideCJC-1295 · StatusWhat is the US regulatory status of CJC-1295?
At the October 3, 2026 check, FDA listed CJC-1295 among withdrawn compounding nominations while retaining its safety warning.[14] That compounding entry is not a drug approval: FDA states that compounded drugs are not FDA-approved and undergo no premarket agency review for safety, effectiveness or quality.[30]
Read in the peptide guideIpamorelin · SafetyWhat safety concerns have been reported with ipamorelin?
FDA flags serious events, including death, reported during intravenous ipamorelin research for gastric motility; this wording does not establish that ipamorelin caused every event.[14] The agency also says evidence is insufficient to characterize harm through certain other injectable routes.[14] The published postoperative trial studied hospitalized surgical patients, so its safety observations cannot establish the safety of long-term use in healthy people.[19]
Read in the peptide guideIpamorelin · ContraindicationsDoes ipamorelin research define who should not use it?
The early pharmacology study enrolled healthy men, while the postoperative trial enrolled adults undergoing bowel resection.[18][19] Those selected populations do not establish a validated contraindication list or demonstrate suitability during pregnancy or childhood; study eligibility should not be presented as a clinical prescribing rule.[18][19]
Read in the peptide guideIpamorelin · InteractionsCan ipamorelin interaction risks be inferred from its GH response?
The pharmacology study measured ipamorelin and GH after infusion; it did not test coadministration with CJC-1295.[18] Our interpretation is that these hormone measurements cannot establish combination safety, added benefit or dose adjustments.[18]
Read in the peptide guideIpamorelin · Forms & dosingDo the published ipamorelin trials establish a subcutaneous dosing protocol?
The cited pharmacology study and postoperative trial used intravenous infusion, with the surgical trial administering treatment in hospital for up to seven days or until discharge.[18][19] Those study regimens do not validate a subcutaneous home-use schedule or a mixture containing other peptides.[18][19]
Read in the peptide guideIpamorelin · Results & stoppingHow quickly does ipamorelin act, and do benefits persist after stopping?
In healthy men receiving intravenous ipamorelin, its terminal half-life was about two hours and GH rose transiently before declining.[18] In the postoperative randomized trial, ipamorelin did not significantly improve the primary or secondary efficacy measures; neither study establishes lasting recovery benefits after stopping.[18][19]
Read in the peptide guideIpamorelin · Product qualityWhy is ipamorelin product characterization important?
FDA identifies potential immune reactions related to aggregation or peptide impurities, and notes that ipamorelin’s unnatural amino acids complicate characterization.[14] For compounded products generally, FDA also warns that contamination or excessive active ingredient can cause serious injury; a product’s availability does not establish its quality.[30]
Read in the peptide guideIpamorelin · StatusWhat is the US regulatory status of ipamorelin acetate?
At the October 3, 2026 check, ipamorelin acetate remained in FDA’s 503B Category 2 and also appeared among withdrawn nominations.[14] These compounding classifications do not constitute approval: compounded drugs are not FDA-approved or reviewed by the agency before marketing for safety, effectiveness and quality.[30]
Read in the peptide guideCollagen peptides · SafetyCan oral collagen peptides cause adverse reactions?
A published case documented anaphylaxis from fish-collagen gummies in a child with fish allergy, with the reaction confirmed by a supervised oral challenge.[35] An eight-week skin trial in 69 adult women cannot estimate rare reactions or establish long-term safety across all collagen sources and products.[26]
Read in the peptide guideCollagen peptides · ContraindicationsWho needs particular caution with collagen supplements?
Known allergy to the source material matters: the challenge-confirmed fish-collagen case demonstrates that processing collagen into a supplement does not guarantee removal of allergenic potential.[35] FDA advises discussing supplement use with a health professional during pregnancy or breastfeeding; this general precaution is not an established collagen-specific contraindication.[36]
Read in the peptide guideCollagen peptides · InteractionsAre collagen supplements compatible with every medication?
FDA advises reviewing supplements alongside medicines because some supplement ingredients can change drug absorption, metabolism or elimination.[36] That general warning does not demonstrate a specific collagen–drug interaction, but it supports checking the complete formulation and medication list instead of assuming that every collagen product is compatible.[36]
Read in the peptide guideCollagen peptides · Forms & dosingDoes one collagen trial establish a dose for every product?
The skin trial tested a specific oral collagen hydrolysate for eight weeks, so its results concern that preparation and study population rather than every collagen formulation.[26] FDA states that supplement serving sizes are set by manufacturers rather than approved by the agency; a label serving is not an independently validated clinical dose.[37]
Read in the peptide guideCollagen peptides · Results & stoppingWhen might collagen results appear, and do they last after stopping?
In one skin trial, measurements were taken at four and eight weeks, followed by a skin-elasticity assessment four weeks after the final intake.[26] The authors reported improved elasticity and some persistence in older participants, but moisture outcomes were not statistically significant and this short follow-up cannot establish permanent changes.[26]
Read in the peptide guideCollagen peptides · Product qualityWhat information matters when evaluating a collagen supplement?
FDA requires supplement manufacturing controls addressing identity, purity, quality, strength and composition, along with ingredient labeling.[37] The animal source is relevant to allergy risk, as demonstrated by the fish-collagen anaphylaxis case.[35] FDA does not test supplements before sale, so a label or legal availability does not establish batch-level verification or clinical benefit.[37]
Read in the peptide guideCollagen peptides · StatusAre oral collagen supplements FDA-approved treatments?
When a collagen product is marketed as a dietary supplement in the United States, FDA does not approve it before sale.[37] A supplement promoted to treat, prevent or cure a disease meets the drug definition, while an ordinary structure/function claim is not an FDA-approved treatment claim.[37]
Read in the peptide guideReferences
37 sources
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (2021)Primary researchRead review · DraftSave study
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (2026)Primary research · PreclinicalRead review · DraftSave study
- Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats (2025)Primary research · PreclinicalReview status · PendingSave study
- Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats (2021)Primary research · PreclinicalReview status · PendingSave study
- Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application (2010)Primary research · PreclinicalReview status · PendingSave study
- Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats (2004)Primary research · PreclinicalReview status · PendingSave study
- Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157 (2021)Primary research · PreclinicalReview status · PendingSave study
- FDA Briefing Document: BPC-157-related bulk drug substances, July 2026 Pharmacy Compounding Advisory Committee (2026)Regulatory assessmentSave study
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (2024)Primary research · Human studyRead review · DraftSave study
- Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes (2026)Primary research · Preprint, not peer reviewedReview status · PendingSave study
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (2025)Primary research · Human studyRead review · DraftSave study
- Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts (2014)Primary research · PreclinicalRead review · DraftSave study
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs (2022)Primary research · PreclinicalReview status · PendingSave study
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Accessed 2026-10-03)Regulatory guidanceSave study
- 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2023)Primary researchReview status · PendingSave study
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006)Primary researchReview status · PendingSave study
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (2006)Randomized controlled trialsReview status · PendingSave study
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999)Human pharmacology studyReview status · PendingSave study
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (2014)Randomized controlled trialReview status · PendingSave study
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)Primary researchReview status · PendingSave study
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022)Primary researchReview status · PendingSave study
- Tirzepatide Once Weekly for the Treatment of Obesity (2022)Primary researchReview status · PendingSave study
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (2025)Primary researchReview status · PendingSave study
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024)Primary researchReview status · PendingSave study
- 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain (2008)Primary researchReview status · PendingSave study
- Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study (2014)Randomized controlled trialReview status · PendingSave study
- Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases (2024)Primary researchReview status · PendingSave study
- WEGOVY U.S. Prescribing Information, revised June 2026 (2026)Regulatory labelingSave study
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (Accessed 2026-10-03)Regulatory assessmentSave study
- Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory guidanceSave study
- ZEPBOUND U.S. Prescribing Information, revised August 2026 (2026)Regulatory labelingSave study
- 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2023)Primary researchReview status · PendingSave study
- Cosmetics & U.S. Law (Accessed 2026-10-03)Regulatory guidanceSave study
- December 4, 2024 Pharmacy Compounding Advisory Committee Meeting: FDA presentation on CJC-1295 (2024)Regulatory assessmentSave study
- A case of pediatric anaphylaxis caused by gummy tablets containing fish collagen (2020)Case reportReview status · PendingSave study
- Mixing Medications and Dietary Supplements Can Endanger Your Health (Accessed 2026-10-03)Regulatory guidanceSave study
- Questions and Answers on Dietary Supplements (Accessed 2026-10-03)Regulatory guidanceSave study
Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions